Success Metrics

Clinical Success Rate

25.0%

Based on 1 completed trials

Completion Rate

25%(1/4)

Active Trials

0(0%)

Results Posted

400%(4 trials)

Terminated

3(75%)

Phase Distribution

Ph phase_3

25%

Ph phase_2

50%

Ph phase_4

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

2(50.0%)

Phase 3Large-scale testing

1(25.0%)

Phase 4Post-market surveillance

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(3)

Detailed Status

Terminated3

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 4

Trials by Phase

Phase 22 (50.0%)

Phase 31 (25.0%)

Phase 41 (25.0%)

Trials by Status

terminated375%

completed125%

Recent Activity

0 active trials

Showing 4 of 4

terminatedphase_3

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT04652700

terminatedphase_2

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

NCT04493216

completedphase_4

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

NCT03350672

terminatedphase_2

Emtricitabine/Tenofovir Alafenamide as Salvage ART

NCT02556333

Clinical Trials (4)

Showing 4 of 4 trials

NCT04652700Phase 3

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Terminated

NCT04493216Phase 2

A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults

Terminated

NCT03350672Phase 4

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

Completed

NCT02556333Phase 2

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4